Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe by Matharu, Manjit et al.
Original Article
Utilization and safety of
onabotulinumtoxinA for the
prophylactic treatment of chronic
migraine from an observational
study in Europe
Manjit Matharu1, Julio Pascual2, Ingela Nilsson Remahl3,
Andreas Straube4, Arlene Lum5, Gudarz Davar5, Dawn Odom6,
Lee Bennett6, Christina Proctor6,*, Lia Gutierrez7,
Elizabeth Andrews8 and Catherine Johannes9
Abstract
Objective: To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment
of chronic migraine in routine clinical practice.
Background: Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic
migraine, but real-world data are limited.
Design/methods: A prospective, observational, post-authorization study in adult patients with chronic migraine trea-
ted with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for
52 weeks for utilization and 64 weeks for safety data, and summarized using descriptive statistics.
Results: Eighty-five physicians (81% neurologists) at 58 practices in the United Kingdom, Germany, Spain, and Sweden
participated and recruited 1160 patients (84.2% female, median age 46.6 years). At baseline, 85.8% of patients had
physician diagnoses of chronic migraine/transformed migraine and reported an average of 11.3 (SD¼ 6.9) severe head-
ache days per 28 days; 50.6% had previously used onabotulinumtoxinA for chronic migraine. A total of 4017 study
treatments were observed. The median number of injection sites (n¼ 31) and total dose (155 U) were consistent across
all treatment sessions, with a median 13.7 weeks observed between sessions. At least one treatment-related adverse
event was reported by 291 patients (25.1%); the most frequently reported treatment-related adverse event was neck
pain (4.4%). Most patients (74.4%) were satisfied/extremely satisfied with onabotulinumtoxinA treatment.
Conclusions: Patient demographics/characteristics are consistent with published data on the chronic migraine popu-
lation. Utilization of onabotulinumtoxinA treatment for chronic migraine appears to be consistent with the Summary of
Product Characteristics and published PREEMPT injection paradigm. No new safety signals were identified.
Keywords
Chronic headache, utilization, adverse events, safety, PREEMPT paradigm
Date received: 14 April 2017; revised: 9 June 2017; 7 July 2017; accepted: 12 July 2017
1Headache Group, Institute of Neurology and The National Hospital for
Neurology and Neurosurgery, London, UK
2Department of Neurology, University Hospital Marqués de Valdecilla
and IDIVAL, Santander, Spain
3Department of Clinical Neuroscience, Division of Neurology, Karolinska
Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
4Department of Neurology, Klinikum Grosshadern, Munich, Germany
5Clinical Development, Allergan plc, Irvine, CA, USA
6Biostatistics, RTI Health Solutions, Research Triangle Park, NC, USA
7Pharmacoepidemiology and Risk Management, RTI Health Solutions,
Barcelona, Spain
8Pharmacoepidemiology and Risk Management, RTI Health Solutions,
Research Triangle Park, NC, USA
9Pharmacoepidemiology and Risk Management, RTI Health Solutions,
Waltham, MA, USA
Corresponding author:
Manjit Matharu, Headache Group, Institute of Neurology and The
National Hospital for Neurology and Neurosurgery, Queen Square,
London WC1N 3BG, UK.
Email: m.matharu@uclmail.net
*Employment at the time of the study.
Cephalalgia
2017, Vol. 37(14) 1384–1397






The pharmacologic management of chronic migraine,
defined as headache occurring on at least 15 days per
month for >3 months in which headache with features
of migraine occur on 8 days per month (1), includes
acute treatment of headaches as well as preventive
therapies to reduce the frequency of headaches and
related migraine disability (2). Chronic migraine has
been estimated to affect approximately 1.4% to 2.2%
of the population globally (3), with rates of 0.4% to
2.0% reported for German populations depending on
how strictly the criteria for chronic migraine were
applied (4). As chronic migraine is often associated
with substantial disability, functional impairment, and
decreased quality of life (5,6), and in many cases may be
associated with medication overuse (7), it is important
that any treatment is both effective and well tolerated.
The efficacy and safety of onabotulinumtoxinA has
been demonstrated in the Phase III Research Evaluating
Migraine Prophylaxis Therapy (PREEMPT) trials (8,9).
In a pooled analysis of four double-blind placebo-
controlled trials, onabotulinumtoxinA was safe and
well tolerated, with 3.4% of patients discontinuing
treatment with onabotulinumtoxinA due to an adverse
event (10). Serious adverse events occurred in 5.4% of
patients receiving onabotulinumtoxinA and 3.0% of
those receiving placebo. Consistent with the known
tolerability profile of onabotulinumtoxinA, the
most frequently reported adverse events in the
pooled analysis were musculoskeletal in origin and
were comparable to the known adverse events asso-
ciated with onabotulinumtoxinA when used in other
indications.
OnabotulinumtoxinA is approved for the prophy-
laxis of headache in adults with chronic migraine
(10,11). There are limited data on the utilization and
safety of onabotulinumtoxinA for chronic migraine in a
clinical setting. Therefore, the goal of this study was to
monitor the utilization practices and describe the safety
profile of onabotulinumtoxinA for chronic migraine
headache prophylaxis in routine clinical practice set-




This was a prospective, observational, multinational
European study (NCT01432379). The study protocol
was reviewed and approved by the relevant ethics
committees in each country. Physicians were recruited
for the study in the United Kingdom, Germany,
Sweden, and Spain, primarily through attendance
at training sessions on the administration of
onabotulinumtoxinA for the management of chronic
migraine educational meetings.
Patient recruitment was targeted to begin 12 months
after regulatory approval in each country, with the first
recruitment in the United Kingdom on September 9,
2011. The recruitment period was 27 months in the
United Kingdom, 16 months in Germany, and
14 months in Spain and Sweden. Patients were followed
up for up to 64 weeks after the baseline treatment, with
the last follow-up visit scheduled for approximately
12 weeks after the final study treatment session at
48 to 52 weeks. The total duration of the study from
the first patient enrollment through to the final follow-
up visit for the last patient was 43 months in the United
Kingdom, 31 months in Germany, 27 months in
Sweden, and 28 months in Spain. The last patient’s
final follow-up visit was conducted in Spain on April
18, 2015.
Study population
The study population consisted of patients receiving
onabotulinumtoxinA therapy for chronic migraine,
recruited by their participating physicians. Patients
were adults aged 18 years and older with a new or
established physician diagnosis of chronic migraine.
All patients were being treated for chronic migraine
headache in routine practice, and could have been
new to treatment with onabotulinumtoxinA for chronic
migraine (treatment naı̈ve) or could have been previ-
ously treated with onabotulinumtoxinA (non-naı̈ve).
The decision to initiate or continue treatment was inde-
pendent of the patients’ enrollment in the study.
Written informed consent was provided by all partici-
pating patients.
OnabotulinumtoxinA exposure
Patients were administered onabotulinumtoxinA in
routine clinical practice for the treatment of chronic
migraine. Although participating physicians were pro-
vided with the Summary of Product Characteristics, the
study protocol did not mandate the treatment para-
digm or frequency of administration as outlined in
the Summary of Product Characteristics. The intent
of the study was to observe treatment utilization and
safety in real-world clinical practice with no study
intervention.
According to the Summary of Product
Characteristics, the recommended dose of
onabotulinumtoxinA is 155U, up to a maximum dose
of 195U, administered intramuscularly using a
30-gauge, 0.5 in needle as 0.1mL (5U) injections into
31 to 39 sites, every 12 weeks (12). The injections are
recommended to be divided across seven specific head
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and neck muscle areas (i.e. frontalis, corrugator, pro-
cerus, occipitalis, temporalis, trapezius, and cervical
paraspinal muscle group) and are recommended to be
injected bilaterally with the exception of the procerus,
which requires one midline injection. In the case of pre-
dominant pain location(s), additional injections can
be administered in up to three specific muscle areas
(i.e. occipitalis, temporalis, and trapezius) (12).
Data sources and measurement
Practice and physician characteristics were collected at
baseline via a questionnaire that captured details
including practice type and characteristics, physician
experience, and number of patients seen. Patient demo-
graphics and clinical characteristics were also collected
at baseline. Medical and migraine-related history at
baseline was captured from the patient’s medical
record. Treatment utilization information was collected
at every treatment session for up to 52 weeks and
included details on onabotulinumtoxinA dose,
number and location of injections, and needle size.
Detailed information on any adverse events and specific
adverse events of special interest, including worsening
of migraine and intractable migraine, reported by
patients and occurring during or between treatment ses-
sions, was collected throughout the study period.
Information pertaining to dysphagia was also collected.
A final follow-up visit was conducted approximately
12 weeks after the final treatment session and collected
data on adverse events that occurred after the final
treatment session in addition to patient reported overall
satisfaction with onabotulinumtoxinA treatment, mea-
sured by a single question using a five-point scale from
extremely satisfied to extremely dissatisfied.
Study size
This study was not designed for hypothesis testing;
therefore, no formal power calculations were per-
formed. The number of patients was chosen based on
a practical basis in conjunction with the ability to detect
rates of adverse events similar to those in phase 3 trials
undertaken previously. With agreement from the
Medicines and Health Product regulatory agents in
the United Kingdom and the Irish Medicines Board,
the final overall study enrollment was targeted at 900
patients, which targeted 320–350 in the United
Kingdom, 250–280 in Germany, 200–210 in Sweden,
and 70–125 in Spain.
Statistical analysis
Data were summarized using descriptive statistics and
stratified by country and prior onabotulinumtoxinA
use. As the analysis was descriptive in nature, statistical
inference was not performed. Any missing data were
excluded from the analysis. Safety data were summar-
ized using terminology from the Medical Dictionary for
Regulatory Activities (MedDRA version 17.1). For
each system organ class and preferred term, the
number and percentage of patients who experienced
adverse events were tabulated. Patients experiencing
more than one adverse event were counted only once
at each MedDRA level. Incidence rates of adverse
events were calculated as the number of new events
occurring during the study period divided by the
person-time at risk and displayed with 95% exact
Poisson confidence intervals.
The analysis population for physicians included the
principal investigator at each site and any additional
physicians/healthcare professionals administering injec-
tions to study patients at that site. The analysis popu-
lation for patients included all patients enrolled in the
study who completed at least one onabotulinumtoxinA
treatment session.
Results
Practice site and physician characteristics
A total of 97 physicians completed the site feasibility
questionnaire and 85 physicians at 58 sites participated
in the study (Figure 1). There were 19 physicians from
16 practice sites in the United Kingdom, 39 physicians
from 19 sites in Germany, 14 physicians from 12 sites in
Sweden, and 13 physicians from 11 sites in Spain.
Among participating sites, 71.4% were specialty-based
practices (specialty practice, 32.1%; headache specialty,
26.8%; headache/pain clinic, 12.5%), 50.0% were hos-










n = 37 (24.5%)
Sweden
n = 21 (52.5%)
Spain
n = 29 (69.0%)
Germany
n = 27 (69.2%)
UK
n = 29 (19.2%)
Sweden
n = 19 (47.5%)
Spain
n = 24 (57.1%)
Germany
n = 25 (64.1%)
UK
n = 19 (12.6%)
at 16 sites
Sweden
n = 14 (35.0%)
at 12 sites
Spain
n = 13 (31.0%
at 11 sites)
Germany
n = 39 (100%)
at 19 sites
Number of physicians contacted (n = 272)
Responded with interest (n = 114)
Completed site feasibility questionnaire (n = 97)
Final number of participating physicians (n = 85)
Figure 1. Overview of physician recruitment by country.
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clinics, and 21.4% were general practice or ambulatory
care practices (Figure 2). Practice characteristics varied
across countries, with specialty practice more common
in Sweden, and general practice/ambulatory care set-
tings more common in Germany and Spain
(Supplementary Figure 1).
Approximately 75% of the practices saw 11
patients with chronic migraine in the three months
prior to the study. The majority of the participating
physicians were identified as neurologists (81.2%;
Figure 2); 75 participating physicians (88.2%) had
previous experience treating patients with
onabotulinumtoxinA for chronic migraine. The average
number of years the physicians were licensed was
18.5 (SD, 9.4) years. The majority of physicians
(67, 78.8%) had attended onabotulinumtoxinA training
for chronic migraine and 75 (88.2%) had previously
prescribed onabotulinumtoxinA for chronic migraine.
Considerable inter-country variability was observed
from a mean (SD) of 21.4 (22.6) patients treated per
physician in Germany to 222.7 (299.0) patients treated
in Spain
Patient characteristics
A total of 1168 patients enrolled in the study, and 1160
completed at least one treatment session (the analysis
patient population). Of these, 783 (67.5%) patients
completed the entire 52-week observation period and


































*Practice characteristic categories are not mutually exclusive; more than one response was allowed.













































Figure 2. Baseline practice and physician characteristics.
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patients were treated for less than the maximum 52-
week observation period; of these, 34 patients were
lost to follow-up. Of the 312 patients who provided a
reason for discontinuing treatment, the most common
reason was lack of efficacy (n¼ 164, 14.1% of the ana-
lysis population; Table 1).
Patients in the analysis population were on average
46.6 (SD, 11.8) years of age, primarily female, and
white (Table 2). Based on the patient’s medical records,
85.8% of patients had a history of chronic migraine or
transformed migraine diagnoses, 51.6% had a docu-
mented diagnosis of migraine, and 24.7% had a docu-
mented diagnosis of medication overuse. At baseline, in
a usual month (defined as 28 days) patients reported
experiencing an average 7.7 (SD, 6.9) headache-free
days, 9.0 (SD, 6.5) days with headache of mild pain
intensity, and 11.3 (SD, 6.9) days with headache of
severe pain intensity. Most patients were receiving
acute or preventive headache medications at baseline,
with nearly half (43.9%) indicating being on 1 acute
and 1 preventive treatment. In addition, half of the
patients (n¼ 587, 50.6%) indicated having used
onabotulinumtoxinA treatment for chronic migraine
in the past. Patient characteristics at baseline were simi-
lar in the treatment-naı̈ve subgroup (Table 2).











Discontinued study 163 (38.6) 111 (38.7) 44 (20.1) 28 (12.1) 346 (29.8)
Reasons for discontinuation, n (%)*
Lack of efficacyy 77 (18.2) 55 (19.2) 18 (8.2) 14 (6.0) 164 (14.1)
Otherz 25 (5.9) 13 (4.5) 15 (6.8) 3 (1.3) 56 (4.8)
Side effect/other health problem 22 (5.2) 11 (3.8) 4 (1.8) 2 (0.9) 39 (3.4)
Lost to follow-up 18 (4.3) 12 (4.2) 1 (0.4) 3 (1.3) 34 (2.9)
Treatment successful/migraines subsidedy 17 (4.0) 9 (3.1) 1 (0.4) 1 (0.4) 28 (2.4)
Treatment too expensive 14 (3.3) 2 (0.7) 1 (0.4) 2 (0.9) 19 (1.6)
Inconvenient to come in for treatment visits 6 (1.4) 8 (2.8) 4 (1.8) 0 (0.0) 18 (1.5)
Injections too painful 6 (1.4) 10 (3.5) 1 (0.4) 0 (0.0) 17 (1.5)
Concerned about risks 3 (0.7) 6 (2.1) 1 (0.4) 2 (0.9) 12 (1.0)
Injections took too much time 0 (0.0) 3 (1.0) 2 (0.9) 1 (0.4) 6 (0.5)
*More than one response was allowed; categories are not mutually exclusive; 312 patients provided 1 reason why treatment was discontinued and 34
patients were lost to follow-up.
y‘‘Lack of efficacy’’ and ‘‘Treatment successful/migraines subsided’’ were categories determined from manual review of the Other category free-text
responses, provided by 238 patients.
zUK: Nine patients reported they were getting or seeking treatment on the National Health Service program; four reported they were no longer
eligible for treatment based on the NICE guidelines; three reported a pregnancy; two reported adverse effects; two moved away or transferred to
another physician; one reported travel distance was too far; one reported treatment was ineffective; one was deceased; two reported other reasons;
Germany: Four patients reported travel distance was too far; three reported a pregnancy; two reported adverse effects; one moved away or
transferred to another physician; three reported other reasons; Sweden: Two patients moved away or transferred to another physician; one reported
adverse effects; one reported a pregnancy; and 11 reported unknown or other reasons; Spain: one patient reported adverse effects; one moved away
or transferred to another physician; one was deceased.
Targeted patient enrollment (n = 965)
Patients enrolled with baseline demographic information (n = 1168)
Number of patients treated (Analysis population) (n = 1160)
Patients who discontinued before study end (n = 346)
Patients who completed entire 52-week observation period but
did not complete final interview (n = 31)
Patients who completed entire 52-week observation period and


























n = 163 (38.6%)
Germany
n = 111 (38.7%)
Sweden
n = 44 (20.1%)
Spain
n = 28 (12.1%)
UK
n = 21 (5.0%)
Germany
n = 9 (3.1%)
Sweden
n = 1 (0.5%)
Spain
n = 0 (0.0%)
UK
n = 238 (56.4%)
Germany
n = 167 (58.2%)
Sweden
n = 174 (79.5%)
Spain
n = 204 (87.9%)
Figure 3. Patient enrollment and disposition.
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OnabotulinumtoxinA utilization
A total of 4017 onabotulinumtoxinA treatment sessions
were administered to patients throughout the course of
the study, with up to seven treatment sessions per
patient. Because only one patient (in Sweden) received
a seventh treatment, data are presented on six treatment
sessions (Table 3). The median total number of sites
injected for each side (right and left) across muscle
areas and across all treatment sessions was 15 sites,
with one site on the midline also injected (median total
number of sites injected was 31 for all treatment cycles 1
to 5). The median total dose of onabotulinumtoxinA
administered across all treatment sessions was 75 U for
each side (right and left) and 5U in the midline (com-
bined median total dose of 155U). The median injection
sites and doses were similar across all countries and were
the same for treatment-naı̈ve patients as for the overall
analysis population (Supplementary Table 1). The
majority of injections were administered using a 0.5 in/
1.25 cm needle length. The muscle areas injected across
treatment sessions were consistent, with the majority of
physicians injecting the seven recommended muscle
areas (Table 4). The muscle areas injected were similar
for the treatment-naı̈ve subgroup (Supplementary Table
2). The average number of weeks between treatment ses-
sions was 14.3 (SD, 3.19) weeks and ranged between 6.0
and 51.4 weeks, with the average time between treatment
sessions generally decreasing slightly with each subse-
quent treatment session (Figure 4).
For the purposes of the study, a deviation from the
treatment paradigm recommended in the Summary of
Product Characteristics was defined as a dose of
<155U or >195U, injection of <31 or> 39 sites, a
dosing interval of <11 or >13 weeks, or use of a
needle of length other than 1.25 cm (0.5 in) or 2.5 cm
(1 in) for any treatment session; there could be more
than one reason for deviation from the recommended
label treatment paradigm. If a patient received a treat-
ment with any of these characteristics at any time
during the study period, the patient was classified as
‘‘deviated’’ regardless of other treatment sessions.
Overall, 1045 (90.1%) patients in the study were
observed to have 1 treatment deviation. Patients in
the United Kingdom were least likely to receive treat-
ment that deviated from the recommended label treat-
ment paradigm (80.1%) and those in Spain were most
likely to do so (99.1%; Supplementary Table 3). The
majority of the deviations documented were deviations
from the recommended dosage schedule, with 844
(72.8%) patients receiving treatment at an interval
greater than 13 weeks. In review of treatment deviations
during the study, where 1 deviation was reported over
the course of up to six treatment sessions, nearly half of
the patients (n¼ 480, 41.4%) were administered a
Table 2. Baseline patient demographics and clinical character-







Mean (SD) age, years 46.3 (11.97) 46.6 (11.8)
Min, max 20, 79 19, 79
Female, n (%) 449 (80.8) 977 (84.2)
Whitey, n (%) 542 (97.5) 1134 (97.8)
Mean (SD) BMI, kg/m2 25.2 (4.8) 25.4 (5.1)
Min, max 16, 44 15, 55
Headache diagnosis historyz, n (%)
Chronic migraine or
transformed migraine
470 (84.5) 995 (85.8)
Migraine 298 (53.6) 599 (51.6)
Medication overuse** 143 (25.7) 286 (24.7)
Tension headache 76 (13.7) 165 (14.2)
Chronic daily headache 49 (8.8) 116 (10.0)
Chronic tension-type
headache
22 (4.0) 52 (4.5)
Intractable/refractory
migraine/headache
13 (2.3) 47 (4.1)
Menstrual headache/
migraine
21 (3.8) 43 (3.7)
Cluster headache 14 (2.5) 27 (2.3)
Stress headache 14 (2.5) 26 (2.2)
New daily persistent
headache
2 (0.4) 8 (0.7)
Sinus headache 4 (0.7) 8 (0.7)
Hemicrania continua 3 (0.5) 6 (0.5)
Other 21 (3.8) 40 (3.4)
Baseline headache medication(s)y
Acute, n (%)
0 82 (14.7) 155 (13.4)
1 208 (37.4) 436 (37.6)
2 152 (27.3) 323 (27.8)
3 114 (20.5) 246 (21.2)
Preventive, n (%)
0 277 (49.8) 564 (48.6)
1 172 (30.9) 338 (29.1)
2 75 (13.5) 187 (16.1)
3 32 (5.8) 71 (6.1)
Acute and preventive, n (%)
At least one acute and at
least one preventive
235 (42.3) 509 (43.9)
Unknown 6 (1.1) 12 (1.0)
*Treatment-naı̈ve patients had not received onabotulinumtoxinA for the
treatment of chronic migraine prior to the study.
yWhite is defined differently by country: United Kingdom, white includes
English, Welsh, Scottish, Irish, British, Gypsy or Irish Traveler, or any
other white background; Germany, white includes white/Caucasian.
zIncludes all headache diagnoses included in the patient’s medical record;
more than one response allowed; categories are not mutually exclusive.
**Includes any diagnosis of medication overuse headache, rebound
headache, or medication/analgesic overuse.
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dose< 155 U during at least one treatment session. A
total of 54 (4.7%) patients received a dose> 195U
during at least one treatment session; however, 626
(54.0%) patients did not have any dose deviations at
any treatment session (i.e. received between 155U and
195U). A third of the patients (n¼ 362, 31.2%) received
onabotulinumtoxinA into< 31 sites during at least one
treatment session, and a quarter (n¼ 299, 25.8%) were
injectedwith a needle length outside of recommendations.
Adverse events
A total of 478 (41.2%) patients reported 1 adverse event
during the study for an overall incidence rate of 53.8 per
1000 patient months (95% CI, 49.0–58.8; Table 5). The
incidence of reported adverse events was lowest in Spain
(31.8 per 1000 patient months [95% CI, 24.9–40.1]) and
Sweden (45.7 [95% CI, 36.5–56.4]) and highest in
Germany (65.3 [95% CI 54.3–77.9]) and the United
Kingdom (68.8 (95% CI, 59.5–79.1]). Treatment-related
adverse events were reported by 291 (25.1%) patients,
resulting in an overall incidence rate of 27.9 per 1000
patient months (95% CI, 24.7–31.2) that varied from
9.9 per 1000 patient months (95% CI, 6.4–14.5) in
Spain to 42.1 per 1000 patient months (95% CI 35.3–
49.7) in the United Kingdom. OnabotulinumtoxinA
treatment was stopped due to a treatment-related adverse
event in 51 (4.4%) of patients (Table 5). A serious adverse
event was reported by 61 (5.3%) patients and 1 (0.1%)
patient reported a treatment-related serious adverse event
(worsening of migraine). Fatal adverse events were
reported in two (0.2%) patients (one patient with myo-
cardial infarction and one patient with metastatic lung
neoplasm); neither was considered related to treatment.
Of the 54 patients who received> 195 U during 1 treat-
ment session, 22 (40.7%) patients reported 1 adverse
event. The adverse event rate in this population was con-
sistent with the total study population. Overall, the per-
centage of patients reporting 1 adverse event declined
with each subsequent treatment session, with 311/1160













Total number of sites injected across muscle areas
Right side, n 1160 1034 884 711 210 15
Median 15 15 15 15 15 15
Min, max 5, 30 4, 29 4, 34 4, 30 4, 30 12, 17
Left side, n 1160 1034 884 711 210 15
Median 15 15 15 15 15 15
Min, max 5, 30 3, 26 3, 34 4, 32 4, 32 12, 22
Midline*, n 1095 977 834 680 198 15
Median 1 1 1 1 1 1
Min, max 1, 6 1, 6 1, 5 1, 4 1, 4 1, 3
Total dose across muscle areas
Right side, n 1160 1034 884 711 210 15
Median 75 75 75 75 75 75
Min, max 30, 146 25, 145 20, 162 20, 146 20, 146 30, 131
Left side, n 1160 1034 884 711 210 15
Median 75 75 75 75 75 75
Min, max 30, 160 6, 175 6, 180 20, 180 20, 180 30, 116
Midline*, n 1095 977 835 681 198 15
Median 5 5 5 5 5 5
Min, max 3, 30 3, 30 3, 120 3, 150 3, 25 5, 25
Needle lengthy,z, n (%)
0.5 in / 1.25 cm 850 (73.3) 798 (77.2) 672 (75.9) 546 (76.7) 163 (77.6) 10 (66.7)
1.0 in / 2.5 cm 111 (9.6) 76 (7.4) 82 (9.3) 67 (9.4) 45 (21.4) 0 (0.0)
Other 279 (23.8) 221 (21.4) 186 (21.0) 147 (20.6) 37 (17.6) 5 (33.3)
*Includes only procerus and ‘‘other’’ midline muscle areas.
yMore than one response allowed; categories are not mutually exclusive.
zSweden, Germany, and Spain have needles 1.25 cm and 2.5 cm in length; United Kingdom has needle lengths of 0.5 inch and 1 inch.
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Frontalis 1154 (99.5) 1027 (99.3) 876 (99.0) 704 (98.9) 208 (99.0) 15 (100)
Corrugator 1131 (97.5) 1006 (97.3) 872 (98.5) 701 (98.5) 206 (98.1) 15 (100)
Occipitalis 1128 (97.2) 1011 (97.8) 870 (98.3) 703 (98.7) 204 (97.1) 15 (100)
Temporalis 1155 (99.6) 1031 (99.7) 878 (99.2) 706 (99.2) 207 (98.6) 15 (100)
Trapezius 1129 (97.3) 1008 (97.5) 864 (97.6) 697 (97.9) 205 (97.6) 15 (100)
Cervical paraspinal 1091 (94.1) 960 (92.8) 820 (92.7) 655 (92.0) 196 (93.3) 15 (100)
Masseter 4 (0.3) 12 (1.2) 18 (2.0) 8 (1.1) 3 (1.4) 1 (6.7)
Other 129 (11.1) 123 (11.9) 103 (11.6) 91 (12.8) 44 (21.0) 4 (26.7)
Left side
Frontalis 1154 (99.5) 1027 (99.3) 876 (99.0) 705 (99.0) 208 (99.0) 15 (100)
Corrugator 1130 (97.4) 1005 (97.2) 872 (98.5) 701 (98.5) 206 (98.1) 15 (100)
Occipitalis 1128 (97.2) 994 (96.1) 859 (97.1) 703 (98.7) 204 (97.1) 15 (100)
Temporalis 1154 (99.5) 1014 (98.1) 868 (98.1) 707 (99.3) 207 (98.6) 15 (100)
Trapezius 1129 (97.3) 993 (96.0) 854 (96.5) 697 (97.9) 205 (97.6) 15 (100)
Cervical paraspinal 1091 (94.1) 944 (91.3) 810 (91.5) 655 (92.0) 196 (93.3) 15 (100)
Masseter 4 (0.3) 12 (1.2) 18 (2.0) 8 (1.1) 3 (1.4) 1 (6.7)
Other 131 (11.3) 123 (11.9) 101 (11.4) 89 (12.5) 46 (21.9) 5 (33.3)
Midline
Procerus 1095 (94.4) 977 (94.5) 834 (94.2) 680 (95.5) 198 (94.3) 15 (100)
Other 18 (1.6) 19 (1.8) 11 (1.2) 10 (1.4) 3 (1.4) 1 (6.7)




















































Figure 4. Mean (SD) time between onabotulinumtoxinA treatment sessions. Dotted line indicates recommended treatment interval
of 12 weeks between treatment sessions. Descriptive statistics only were undertaken, and there were no intergroup tests of statistical
significance performed.
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(26.8%) patients reporting 1 adverse event at treatment
session 1 and 39/210 (18.6%) patients doing so by treat-
ment session 5.
For the adverse events of special interest, worsening of
migraine occurred most frequently (101 of 1160 patients,
8.7%) and was considered serious in six (0.5%) patients.
The highest percentage of patients reporting 1 worsen-
ing of migraine event was observed in Spain (12.5%) and
the lowest in Sweden (5.5%). Intractable migraine
occurred in 20 (1.7%) patients, and was considered ser-
ious in three (0.3%) patients. Hypersensitivity reactions,
none of which were serious, occurred in 17 (1.5%)
patients and dysphagia in five (0.4%). The most com-
monly reported treatment-related adverse event of special
interest was worsening of migraine (n¼ 46, 4.0%). All
other treatment-related adverse events of special interest
were reported in< 1% of the study population (Table 5).
The most commonly reported treatment-related
adverse event was neck pain (n¼ 51, 4.4%; Table 6).











Patients with 1 adverse
event, n (%)
197 (46.7) 123 (42.9) 86 (39.3) 72 (31.0) 478 (41.2)
Incidence per 1000 patient
months (95% CI)
68.8 (59.5–79.1) 65.3 (54.3–77.9) 45.7 (36.5–56.4) 31.8 (24.9–40.1) 53.8 (49.0–58.8)
Serious adverse events, n (%) 20 (4.7) 16 (5.6) 16 (7.3) 9 (3.9) 61 (5.3)
Treatment discontinued due to
adverse events, n (%)
27 (6.4) 16 (5.6) 5 (2.3) 3 (1.3) 51 (4.4)
Special interest adverse events, n (%)
Worsening of migraine 41 (9.7) 19 (6.6) 12 (5.5) 29 (12.5) 101 (8.7)
Intractable migraine 2 (0.5) 8 (2.8) 2 (0.9) 8 (3.4) 20 (1.7)
Hypersensitivity 11 (2.6) 1 (0.3) 4 (1.8) 1 (0.4) 17 (1.5)
Dysphagia 3 (0.7) 1 (0.3) 0 (0.0) 1 (0.4) 5 (0.4)
Fatal adverse events, n (%) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.4) 2 (0.2)
Treatment-related adverse events
Patients with 1 treatment-related
adverse events, n (%)
138 (32.7) 88 (30.7) 39 (17.8) 26 (11.2) 291 (25.1)
Incidence per 1000 patient
months (95% CI)
42.1 (35.3–49.7) 40.2 (32.3–49.6) 16.7 (11.8–22.8) 9.9 (6.4–14.5) 27.9 (24.7–31.2)
Serious treatment-related
adverse events, n (%)
1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (< 0.1)
Special interest treatment-related adverse events, n (%)
Worsening of migraine 28 (6.6) 10 (3.5) 7 (3.2) 1 (0.4) 46 (4.0)
Intractable migraine 0 (0.0) 3 (1.0) 0 (0.0) 2 (0.9) 5 (0.4)
Hypersensitivity 7 (1.7) 0 (0.0) 2 (0.9) 1 (0.4) 10 (0.9)
Dysphagia 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.3)
Fatal treatment-related
adverse events, n (%)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
*Treatment-naı̈ve patients have not previously received onabotulinumtoxinA for the treatment of chronic migraine.
Table 6. Treatment-related adverse events reported by 1% of







Neck pain 30 (5.4) 51 (4.4)
Eyelid ptosis 24 (4.3) 47 (4.1)
Muscular weakness 16 (2.9) 31 (2.7)
Headache 14 (2.5) 26 (2.2)
Musculoskeletal stiffness 14 (2.5) 23 (2.0)
Migraine 12 (2.2) 34 (2.9)
Facial paresis 7 (1.3) 15 (1.3)
Facial spasm 7 (1.3) 11 (0.9)
Myalgia 7 (1.3) 11 (0.9)
Pruritus 7 (1.3) 7 (0.6)
Musculoskeletal pain 6 (1.1) 10 (0.9)
*Treatment-naı̈ve patients have not previously received
onabotulinumtoxinA for the treatment of chronic migraine.
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The proportion of patients reporting 1 adverse events
and treatment-related adverse events observed in the
treatment-naı̈ve population were similar to those
observed in the overall study population (Table 6).
Patient satisfaction with treatment
Overall, 1090 patients responded to the treatment sat-
isfaction question during the final interview (n¼ 783 for
those completing 52 weeks of treatment and n¼ 307 for
those treated for less than 52 weeks). The majority of
patients (74.4%) expressed satisfaction (extremely satis-
fied/satisfied) with onabotulinumtoxinA treatment for
chronic migraine (Figure 5a). Patient-reported satisfac-
tion differed by country; the proportion of patients
extremely satisfied/satisfied was lowest in Germany
(61.3%) and highest in Spain (86.0%). Patient-reported
satisfaction differed according to whether patients com-
pleted the entire 52-week observation period (90.1%
[705/783] extremely satisfied/satisfied) or were treated
for less than 52 weeks (34.5% [106/307] extremely satis-
fied/satisfied) (Figure 5a). Satisfaction among patients
who had previously received onabotulinumtoxinA
treatment was higher than the satisfaction observed
with treatment-naı̈ve patients (Figure 5b). Among
those who were treatment-naı̈ve, 338 of 519 (65.1%)
were extremely satisfied/satisfied with treatment. The
proportion of patients reporting satisfaction with treat-
ment was lower among treatment-naı̈ve patients who
were treated for less than the 52-week study period
(46/183, 25.1%) than among those who were treated
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Figure 5. Patient-reported satisfaction with onabotulinumtoxinA treatment for chronic migraine: (a) Overall population stratified by
study disposition; (b) stratified by onabotulinumtoxinA treatment history (n¼ 1070). Data on prior use of onabotulinumtoxinA for
chronic migraine were available for 1136 patients out of the 1160 patients in the analysis population.
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Discussion
The safety and efficacy of onabotulinumtoxinA has
been established in controlled trials (8,9); however,
real-world data in an actual clinical setting are limited.
This study examined the utilization patterns and safety
of onabotulinumtoxinA in a routine clinical setting. As
such, efficacy and effectiveness were not specifically
examined. Consistent with other published studies of
chronic migraine, the majority of patients in the study
had a diagnosis of chronic migraine at their baseline
visit (6,10,13–16). Although other diagnoses were also
recorded, it is likely that migraine and chronic migraine
diagnoses overlapped, in addition to tension-type head-
ache and medication overuse headache. Overall, patient
demographics and clinical characteristics align with
typical chronic migraine characteristics; therefore, this
study was successful in enrolling and observing chronic
migraine patients in a real-world setting.
The doses and muscle areas injected were generally
consistent across treatment sessions and with the
Summary of Product Characteristics and PREEMPT
injection guidelines (12,17). Approximately half of the
patients received the recommended 155 U to 195 U
dose during all their treatment sessions. Of those treat-
ments that deviated from the recommended paradigm,
the majority (72.8%) deviated due to longer treatment
intervals (i.e.> 13 weeks between treatments). Although
approximately 41% of patients received doses< 155U,
this may be an artifact of packaging restrictions for
onabotulinumtoxinA (availability of 50U, 100U, or
200U vials only). Indeed 205 patients (17.7%)
received exactly 150U of onabotulinumtoxinA in 1
treatment session. As this was an observational study
of routine clinical practice in which the treatment
schedule was not specified and instead depended on
physicians’ judgment and patient preferences, variabil-
ity in treatment intervals is to be expected.
Adverse events were consistent with the product
label and with the results from the PREEMPT trials
(8,9,12,18). The percentage of patients reporting 1
adverse event was generally lower than that reported
from previous pooled registration studies (41.2% vs
72.9%) (10), but the percentage of patients with 1
serious adverse event was similar (5.3% vs. 5.4%)
(10). A reported adverse event rate in a clinical practice
setting lower than that reported in a controlled study
environment is in line with the expectation that adverse
event reporting would be less stringent in an observa-
tional study than in a clinical trial. The observed find-
ings also suggest that patients or physicians could have
tended to under-report non-serious adverse events.
Although the overall incidence of adverse events was
lower in our observational study, the nature of the most
frequently reported adverse events was similar to that
reported in clinical trials and included neck pain, mus-
cular weakness, headache, facial paresis and musculo-
skeletal stiffness.
In general, the adverse event incidence rate decreased
with each subsequent treatment session, a finding also
reported by Diener et al. in a pooled analysis of
PREEMPT trials (10). It is likely that the reduction in
adverse events reflects the fact that patients experiencing
fewer benefits and experiencing adverse events discon-
tinued treatment sooner than those with higher per-
ceived benefit and greater tolerability. The observation
that many patients with adverse events continued treat-
ment with onabotulinumtoxinA suggests that these
patients experienced a degree of satisfaction/benefit
with treatment that outweighed the reported adverse
event.
Adverse events associated with potential distant
spread of toxin were also assessed, using a conservative
approach where all potential cases were counted. No
new or unexpected findings were reported from this
assessment.
Although the evaluation of efficacy data was not the
objective of this observational study, results of the one
question on patient-reported satisfaction obtained
during the final follow-up interview revealed an overall
high level of patient satisfaction by those patients
who completed the entire 52-week observational
period and attended the final interview. In a post hoc
analysis stratified by prior treatment status, the sub-
group of patients who had previously received
onabotulinumtoxinA for chronic migraine reported
higher satisfaction (83.6% of those using
onabotulinumtoxinA in the previous six months were
extremely satisfied or satisfied) than the treatment-
naı̈ve subgroup of patients (65.1% were extremely satis-
fied or satisfied). It should be noted that patients in
these subgroups had a varying number of treatment
cycles; typically, at least two to three treatment cycles
repeated every 12 weeks are required to determine
responsiveness to onabotulinumtoxinA in patients
with chronic migraine (19). Because stratification by
prior treatment status was a post hoc analysis, these
results should be interpreted with caution. Treatment-
naı̈ve patients may provide a more accurate
‘‘real-world’’ indication of satisfaction for people new
to treatment with onabotulinumtoxinA.
This study is not without its limitations. The design
of this study allowed for the observation of
onabotulinumtoxinA utilization in actual clinical prac-
tice from a diverse sample of physicians and practices,
which may increase the generalizability of the data.
However, the majority of the physicians were specialists
with prior experience with onabotulinumtoxinA for
chronic migraine; therefore, the data may more closely
reflect results from specialists who have previously
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treated patients with onabotulinumtoxinA in the coun-
tries studied than clinicians new to using the therapy. In
addition, the study population included both patients
who were treatment-naı̈ve and those who had previ-
ously used onabotulinumtoxinA for chronic migraine.
These two groups can have a different safety experi-
ence. It has been shown that for many therapeutic
products, the rate at which adverse events occur
varies with time, with increased risk occurring early
after the initiation of therapy (20). As the study was
initiated so soon after market authorization approval
in each of the participating countries, it was unexpected
that> 50% of patients would have previously received
onabotulinumtoxinA for chronic migraine. As a result
of this unexpected finding, we stratified safety results on
prior use of onabotulinumtoxinA in a post hoc ana-
lysis. Those who had used onabotulinumtoxinA
within the six months before the study also had a
lower incidence rate per 1000 person-months of discon-
tinuation of treatment due to an adverse event
(2.4, 95% CI, 1.3–4.0) than did the treatment-naı̈ve
subgroup (5.2, 95% CI, 3.6–7.4). Again, due to the
post hoc nature of this analysis, these results must be
interpreted with caution.
Those patients who had experienced positive results
and tolerable adverse events after prior treatment with
onabotulinumtoxinA would be more likely to be trea-
ted than patients who either experienced poor clinical
outcomes or intolerable adverse events. Patients who
were treatment-naı̈ve therefore arguably provide data
that may be more generalizable to new users of
onabotulinumtoxinA in a real-world clinical setting.
However, a real-world setting would likely include a
mix of patients (naı̈ve and non-naı̈ve); hence, to observe
utilization in a routine clinical practice, we included a
mix of patients in our study. Finally, with regards to
safety data, the observed adverse events and incidence
rate of adverse events were consistent with the
Summary of Product Characteristics and previously
published results.
Overall, this study captured utilization and safety
data from a large population of chronic migraine
patients treated primarily in headache or pain specialty
clinics or at hospital based practices across four
countries in Europe, providing a comprehensive look
at real-world practices of onabotulinumtoxinA for the
prophylactic treatment of chronic migraine in these
practice settings.
To our knowledge, this is the largest observational
study to date examining utilization and safety of
onabotulinumtoxinA for chronic migraine in actual clin-
ical practice. Results from this study indicate that real-
world utilization of onabotulinumtoxinA for chronic
migraine appears to be consistent with the recommen-
dations in the Summary of Product Characteristics and
the published PREEMPT injection paradigm. No new
safety signals were identified in this study, and the data
continue to support the favorable safety profile of
onabotulinumtoxinA for chronic migraine headache
prophylaxis.
Clinical implications
. Results from this study indicate that real-world utilization of onabotulinumtoxinA for chronic migraine
appears to be consistent with the recommendations in the Summary of Product Characteristics and the
published PREEMPT injection paradigm.
. No new safety signals were identified in this study, and the data continue to support the favorable safety and
tolerability profile of onabotulinumtoxinA for chronic migraine headache prophylaxis.
. The majority of patients reported they were satisfied or extremely satisfied with onabotulinumtoxinA treat-
ment for chronic migraine.
. This study was able to capture utilization and safety data from a large population of chronic migraine
patients across four countries in Europe, providing a comprehensive look at real-world practices of
onabotulinumtoxinA for the prophylactic treatment of chronic migraine.
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